Irlandia - Inggris - HPRA (Health Products Regulatory Authority)

pco manufacturing - tizanidine hydrochloride - tablets - 4 milligram - other centrally acting agents

Inggris - Inggris - MHRA (Medicines & Healthcare Products Regulatory Agency)

teva uk ltd - tizanidine hydrochloride - oral tablet - 2mg

Inggris - Inggris - MHRA (Medicines & Healthcare Products Regulatory Agency)

teva uk ltd - tizanidine hydrochloride - oral tablet - 4mg

Inggris - Inggris - MHRA (Medicines & Healthcare Products Regulatory Agency)

dowelhurst ltd - tizanidine hydrochloride - oral tablet - 2mg

Inggris - Inggris - MHRA (Medicines & Healthcare Products Regulatory Agency)

dowelhurst ltd - tizanidine hydrochloride - oral tablet - 4mg

Tanzania - Inggris - Tanzania Medicinces & Medical Devices Authority

curett health solutions pvt ltd, tanzania - physiotherapy machine -

Irlandia - Inggris - HPRA (Health Products Regulatory Authority)

mundipharma pharmaceuticals limited - oxycodone hydrochloride, naloxone hydrochloride - tablet prolonged release - 2.5 / 1.25 milligram - 02aa55

Amerika Serikat - Inggris - NLM (National Library of Medicine)

karalex pharma llc - fenofibrate (unii: u202363uos) (fenofibrate - unii:u202363uos) - fenofibrate 54 mg - fenofibrate tablets are indicated as adjunctive therapy to diet to reduce elevated ldl-c, total-c, triglycerides and apo b, and to increase hdl-c in adult patients with primary hypercholesterolemia or mixed dyslipidemia (fredrickson types iia and iib). lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and non-pharmacological interventions alone has been inadequate (see national cholesterol education program [ncep] treatment guidelines, below). fenofibrate tablets are also indicated as adjunctive therapy to diet for treatment of adult patients with hypertriglyceridemia (fredrickson types iv and v hyperlipidemia). improving glycemic control in diabetic patients showing fasting chylomicronemia will usually reduce fasting triglycerides and eliminate chylomicronemia thereby obviating the need for pharmacologic intervention. markedly elevated levels of serum triglycerides (e.g. > 2,000 mg/dl) may increase the risk of developing pancreatitis.

Amerika Serikat - Inggris - NLM (National Library of Medicine)

karalex pharma llc - levetiracetam (unii: 44yrr34555) (levetiracetam - unii:44yrr34555) - levetiracetam is indicated as adjunctive therapy in the treatment of partial onset seizures in adults and children 4 years of age and older with epilepsy. levetiracetam is indicated as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents 12 years of age and older with juvenile myoclonic epilepsy. levetiracetam is indicated as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in adults and children 6 years of age and older with idiopathic generalized epilepsy. this product should not be administered to patients who have previously exhibited hypersensitivity to levetiracetam or any of the inactive ingredients in levetiracetam tablets. the abuse and dependence potential of levetiracetam has not been evaluated in human studies.

Amerika Serikat - Inggris - NLM (National Library of Medicine)

karalex pharma, llc, woodcliff lake, nj 07677 - malathion (unii: u5n7su872w) (malathion - unii:u5n7su872w) - malathion 5 mg in 1 ml - malathion lotion is indicated for patients infected with pediculus humanus capitis (head lice and their ova) of the scalp hair. malathion lotion is contraindicated for neonates and infants because their scalps are more permeable and may have increased absorption of malathion. malathion lotion should also not be used on individuals known to be sensitive to malathion or any of the ingredients in the vehicle. the safety and effectiveness of malathion lotion in children less than 6 years of age has not been established via well-controlled trials.